Drug utilisation study of upadacitinib (Rinvoq™) in Europe to evaluate the effectiveness of additional risk minimisation measures

12/02/2021
28/01/2026
EU PAS number:
EUPAS39211
Study
Ongoing

ENCePP Code of conduct

No
Data sources

Data source(s)

Data source(s), other

ARTIS Sweden, DANBIO Denmark, BIOBADASER Spain, RABBIT Germany

Data sources (types)

Administrative healthcare records (e.g., claims)
Disease registry
Other

Data sources (types), other

Prospective patient-based data collection
Use of a Common Data Model (CDM)

CDM mapping

No
Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown
Data characterisation

Data characterisation conducted

No